<SEC-DOCUMENT>0001683168-17-001055.txt : 20170501
<SEC-HEADER>0001683168-17-001055.hdr.sgml : 20170501
<ACCEPTANCE-DATETIME>20170501060203
ACCESSION NUMBER:		0001683168-17-001055
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170501
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170501
DATE AS OF CHANGE:		20170501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SIMULATIONS PLUS INC
		CENTRAL INDEX KEY:			0001023459
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373]
		IRS NUMBER:				954595609
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32046
		FILM NUMBER:		17798355

	BUSINESS ADDRESS:	
		STREET 1:		42505 10TH STREET WEST
		CITY:			LANCASTER
		STATE:			CA
		ZIP:			93534-7059
		BUSINESS PHONE:		661-723-7723

	MAIL ADDRESS:	
		STREET 1:		42505 10TH STREET WEST
		CITY:			LANCASTER
		STATE:			CA
		ZIP:			93534-7059
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>simulations_8k.htm
<DESCRIPTION>CURRENT REPORT ON FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-size: 12pt"><B>UNITED STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>SECURITIES
AND EXCHANGE </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR SIZE="2" NOSHADE ALIGN="CENTER" STYLE="width: 25%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.75in; text-align: center; text-indent: -3.75in">May 1,
2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<HR SIZE="2" NOSHADE ALIGN="CENTER" STYLE="width: 25%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Simulations Plus, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 32%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>California</U></B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>001-32046</U></B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>95-4595609</U></B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer</FONT><BR>
<FONT STYLE="font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>42505 10th Street West, Lancaster, California
93534-7059 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices, including
zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>661-723-7723 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 5pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left">&#9744;</TD><TD STYLE="width: 5pt; text-align: left"></TD><TD STYLE="text-align: left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left">&#9744;</TD><TD STYLE="width: 5pt; text-align: left"></TD><TD STYLE="text-align: left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left">&#9744;</TD><TD STYLE="width: 5pt; text-align: left"></TD><TD STYLE="text-align: left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: left">&#9744;</TD><TD STYLE="width: 5pt; text-align: left"></TD><TD STYLE="text-align: left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="color: #231F20; font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: right">Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <B>Item 1.01</B> <B>Entry into Material Definitive Agreement.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Stock Purchase Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 1, 2017, Simulations Plus, Inc., a California
corporation (the &ldquo;Company&rdquo;), entered into a Stock Purchase Agreement (the &ldquo;Agreement&rdquo;) with DILIsym Services,
Inc., a North Carolina corporation (&ldquo;DILIsym&rdquo;), the shareholders of DILIsym (the &ldquo;DILIsym Shareholders&rdquo;)
and Brett A. Howell, the representative of the DILIsym Shareholders (the &ldquo;DILIsym Shareholders Representative&rdquo;), each,
a &ldquo;Party,&rdquo; and collectively, the &ldquo;Parties.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the terms of the Agreement, and
subject to the satisfaction or waiver of the conditions set forth in the Agreement, the Company shall acquire all of DILIsym&rsquo;s
outstanding capital stock and, in exchange, shall pay to the DILIsym Shareholders: (1) Five Million Dollars ($5,000,000) payable
at the Closing (as defined in the Agreement), subject to certain adjustments and holdbacks as provided in the Agreement; and (2)
certain Earn-Out (as defined in the Agreement) payments, to be measured by the earnings of DILIsym before income taxes, payable
following the Closing, as more particularly described in the Agreement (the &ldquo;Acquisition&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the terms and subject to the conditions
of the Agreement, at the Closing, DILIsym will become a wholly owned subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the Agreement, DILIsym has made certain
representations and warranties to the Company and the parties agreed to certain covenants. Among the covenants set forth in the
Agreement, neither DILIsym, the DILIsym Shareholders nor any of their representatives may participate in any discussions or negotiations
with, or provide any information to, any person or entity with respect to any potential acquisition transaction or enter into any
agreement with respect to such a transaction. Further, each of the DILIsym Shareholders has agreed to enter into a noncompetition
agreement with the Company, each of the officers and directors of DILIsym have agreed to resign immediately prior to the Closing
and the DILIsym Shareholders have agreed to take, or cause DILIsym to take, all actions necessary to cancel, rescind and/or exercise
all stock options of DILIsym outstanding, whether or not exercisable, whether or not vested as of the Closing, which are outstanding
immediately prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Agreement includes customary representations,
warranties and covenants by the Parties. Each Party has agreed, among other things, (i) to generally conduct its business in the
ordinary course consistent with past practice during the interim period between the execution of the Agreement and the Closing
(other than agreed actions to be taken in anticipation of the Closing); (ii) not to engage in certain types of transactions during
this period; and (iii) to secure all necessary approvals to ratify the Agreement and the Acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Consummation of the Acquisition is subject
to various closing conditions, including, (i) the absence of any law, injunction, judgment or ruling enjoining or prohibiting
the Acquisition; (iii) the accuracy of the representations and warranties made by the Parties immediately prior to Closing; (iv)
the performance by the parties in all material respects of their covenants, obligations and agreements under the Agreement; (v)
the absence of any material adverse changes to the businesses and operations of the Company or DILIsym; and (vi) the completion
and delivery of audited financial statements of DILIsym to the Company along with the delivery of a certificate certifying that,
among other things, the audited financial statements of DILIsym (A) present fairly in all material respects the financial position,
assets and liabilities of DILIsym; (B) are in accordance with the books and records of DILIsym and do not reflect any transactions
which are not bona fide transactions; (C) make full and adequate disclosure of, and provision for, all material obligations and
liabilities of DILIsym; and (D) do not include any assets or liabilities of any other Person (as defined in the Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The
Agreement contains customary termination rights for the Parties, including: (i) by mutual consent of the Company and the DILIsym
Shareholders&rsquo; Representative; (ii) by the Company or the DILIsym Shareholders&rsquo; Representative, upon a material breach
of any representation, warranty, covenant, or agreement on the part of any other Party, as set forth in the Agreement; (iii) by
either the Company or the DILIsym Shareholders&rsquo; Representative, if there is any decree, judgment, injunction, or other order
of any governmental entity that is final and non-appealable and that restricts, prevents, or prohibits the consummation of the
Acquisition; or (iv) by either the Company or the DILIsym Shareholders&rsquo; Representative if the Closing shall not have occurred
on or before June 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I<B>tem 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Nominating Committee of the Company&rsquo;s
Board of Directors (the &ldquo;Board&rdquo;) nominated Dr. Daniel Weiner to fill the vacancy on the Board that had been vacated
upon the retirement of Dr. David D&rsquo;Argenio on November 28, 2016. The Board unanimously voted to appoint Dr. Weiner to join
the Board effective May 1, 2017. He will hold this position until the next annual meeting of the Company&rsquo;s shareholders or
until his successor is elected and qualified, subject to his earlier resignation or removal. Dr. Weiner was chosen for his extensive
expertise and his experience in quantitative systems pharmacology software development and model-based drug development, along
with his many years of executive management experience. It is expected that Dr. Weiner will be named as a member of the Audit Committee
as well as the Nominations and Compensation committees of the Board. There is no arrangement or understanding between Dr. Weiner
and any other person pursuant to which Dr. Weiner was selected as a director of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Weiner also serves on the Board of Directors
of DILIsym. Dr. Weiner owns 5,000 shares of DILIsym&rsquo;s common stock (less than one percent of DILIsym&rsquo;s outstanding
shares). At the closing of the Acquisition, Dr. Weiner will receive approximately $64,000 in consideration of the sale of his shares
of DILIsym to the Company. Dr. Weiner does not have any other direct or indirect material interest in any existing or proposed
transaction to which the Company is or may become a participant required to be disclosed by Item 404(a) of Regulation S-K under
the Securities Exchange Act of 1934, as amended. Other than the Company&rsquo;s formal plan for compensating its directors for
their services, whereby each independent director receives $2,000 per meeting of the Board attended, 5,000 non-qualified stock
options per fiscal year, and an annual stipend of $9,000, there are no plans, contracts or arrangements or amendments to any plans,
contracts or arrangements entered into with Dr. Weiner in connection with his election to the Board, nor are there any grants or
awards made to Dr. Weiner in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 7.01 Regulation FD Disclosure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 1, 2017, the Company issued a press
release announcing that it has entered into the Agreement with DILIsym. A copy of the press release is attached hereto as Exhibit
99.1 and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 1, 2017, the Company issued a press
release announcing that Dr. Weiner had been appointed to the Board effective May 1, 2017. A copy of the press release is attached
hereto as Exhibit 99.2 and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">99.2</TD><TD STYLE="text-align: justify">Press release Dated May 1, 2017</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">99.2</TD><TD STYLE="text-align: justify">Press release Dated May 1, 2017</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information in this
Current Report on Form 8-K furnished pursuant to Item 7.01, including the exhibit thereto (the &ldquo;Item 7.01 Information&rdquo;)
is not deemed to be &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (&ldquo;Exchange
Act&rdquo;), or otherwise subject to the liabilities of that section, and such information is not incorporated by reference into
any registration statements or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, whether
made before or after the date hereof, regardless of the general incorporation language contained in such filing, except as shall
be expressly set forth by specific reference to this filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">By providing the Item
7.01 Information, the Company makes no admission as to the materiality of the Item 7.01 Information. The Item 7.01 Information
is intended to be considered in the context of the Company&rsquo;s filings with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;)
and other public announcements that the Company makes, by press release or otherwise, from time to time. The Company undertakes
no duty or obligation to publicly update or revise the Item 7.01 Information, although it may do so from time to time as its management
believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press
releases or through other public disclosure</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37.1pt">This Current Report on
Form 8-K may contain forward-looking statements that are made pursuant to the safe harbor provisions of Section 21E of the Exchange
Act. The forward-looking statements in this Current Report on Form 8-K are not historical facts, do not constitute guarantees of
future performance and are based on numerous assumptions which, while believed to be reasonable, may not prove to be accurate.
Any forward-looking statements in this Current Report on Form 8-K do not constitute guarantees of future performance and involve
a number of factors that could cause actual results to differ materially, including risks more fully described in the Company&rsquo;s
most recently filed Quarterly Report on Form 10-Q and Annual Report on Form 10-K. The Company assumes no obligation to update any
forward-looking information contained in this Current Report.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">SIMULATIONS PLUS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: right"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;/s/ John R. Kneisel</FONT></TD>
    <TD STYLE="width: 17%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>John R. Kneisel</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Chief Financial Officer</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: <B>May 1, 2017</B></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>simulations_8k-ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="logo.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">For Further Information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Simulations Plus, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">42505 10<SUP>th</SUP> Street West</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Lancaster, CA 93534-7059</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt"><B>CONTACT</B>:</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: underline"><U>Simulations Plus Investor Relations</U></TD>
    <TD STYLE="text-decoration: underline"><U>Hayden IR</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Ms. Ren&eacute;e Bouch&eacute;</TD>
    <TD>Mr. Cameron Donahue</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>661-723-7723</TD>
    <TD>651-653-1854</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>renee@simulations-plus.com</TD>
    <TD>cameron@haydenir.com</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">For Immediate Release:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">May 1, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Simulations Plus to Acquire DILIsym Services,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Accretive acquisition to expand Simulations
Plus offerings by adding leading <BR>
provider of drug-induced liver injury (DILI) software and consulting services </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>LANCASTER, CA, May 1, 2017 &ndash; </B>Simulations
Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development,
today announced that it has entered into a Stock Purchase Agreement (the &ldquo;Agreement&rdquo;) with DILIsym Services, Inc. of
Research Triangle Park, North Carolina.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Agreement, upon closing, DILIsym
Services, Inc. (&ldquo;DILIsym Services&rdquo;) will become a wholly owned subsidiary of Simulations Plus, Inc. (&ldquo;Simulations
Plus&rdquo;) and will continue to operate under the DILIsym Services name. This accretive acquisition will result in the total
number of Simulations Plus employees increasing from 68 to 79, and is expected to add more than $3 million to the revenues of the
combined company in the coming fiscal year 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Walt Woltosz, chairman and chief executive
officer of Simulations Plus said, &ldquo;This is an exciting step forward for both Simulations Plus and DILIsym Services. The combination
will significantly strengthen our software and consulting services efforts, and bolster our management team as well. I am pleased
that the existing management team of DILIsym Services will remain with the company. The officers of DILIsym Services will be Dr.
Brett Howell, who will serve as president, Dr. Scott Siler, who will serve as chief scientific officer, and Dr. Bud Nelson, who
will serve as director of operations. In the aggregate, these three leaders have more than 50 years of relevant experience. I will
remain as Chairman and CEO of Simulations Plus, overseeing all three divisions (Simulations Plus, DILIsym Services, and Cognigen
Corporation). In addition, Professor Paul Watkins, M.D., of the University of North Carolina, internationally recognized as the
foremost authority on drug-induced liver injury, will continue as the director of the DILI-sim Initiative Consortium and chairman
of the Initiative&rsquo;s Scientific Advisory Board. This consortium is an international group of twelve pharmaceutical companies
that fund the ongoing development of the DILIsym<FONT STYLE="color: #262626">&reg;</FONT> software.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">Dr. Brett Howell added, &ldquo;<FONT STYLE="color: #262626">Drug-induced
liver injury (DILI) is a rare adverse drug reaction and is the leading cause for acute liver failure in the United States. It is
also the most common factor that compels regulatory actions related to drugs, such as denial of approval or restriction of indications
for using a drug. It is a prime area of concern for the U.S. Food and Drug Administration and other regulatory agencies worldwide.
The DILIsym&reg; software is the most advanced mechanistic mathematical model of drug-induced liver injury, simulating the mechanistic
interactions and events from drug administration through the progression of liver injury and regeneration. DILIsym Services scientists
have supported our customers to present results of DILIsym simulations to several regulatory agencies. We are excited to join Simulations
Plus and take advantage of the various synergies that exist between the organizations.</FONT>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">John Kneisel, chief financial
officer of Simulations Plus, added, &ldquo;We expect this deal will be immediately accretive to both revenues and earnings, and
will not affect our ability to continue to distribute dividends. Of course, the Board of Directors determines the dividend each
quarter and has the option of continuing, increasing, decreasing, or eliminating it at any time to meet the cash needs of the business.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>The Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Agreement calls for the acquisition of
DILIsym Services by Simulations Plus with DILIsym Services becoming a wholly owned subsidiary of Simulations Plus following the
closing of the acquisition, which is subject to final due diligence and other closing conditions. The closing date of the proposed
acquisition is anticipated to be June 1, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the terms of the Agreement, Simulations
Plus will pay the shareholders of DILIsym Services cash consideration of up to $10 million, comprised of $5 million up front plus
an earn-out of up to an additional $5 million over the next three years, based on the profitability of the DILIsym Services division.
The Agreement provides that $1 million of the total up-front consideration will be held back for 18 months to satisfy any indemnifiable
claims that may arise pursuant to the terms of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Excel Partners, an investment bank with offices
in New York and Los Angeles, acted as exclusive financial advisor to Simulations Plus in connection with this transaction. Procopio,
Cory, Hargreaves &amp; Savitch LLP served as legal counsel to Simulations Plus in connection with this transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>About Simulations Plus, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Simulations Plus, Inc., is a premier developer
of groundbreaking drug discovery and development simulation and modeling software that is licensed to and used in the conduct of
drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. Simulations Plus is
headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol &ldquo;SLP.&rdquo; For more information,
visit our Web site at www.simulations-plus.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About DILIsym Services, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">DILIsym Services, Inc. was founded in 2015
in Research Triangle Park, North Carolina, and is the leading provider of drug-induced liver injury simulation software and related
consulting services to the pharmaceutical industry. The company spun out of the former Hamner Institutes, acquiring all of the
intellectual property, software, documentation, and other materials for the DILIsym&reg; software. The company&rsquo;s other products
include MITOsym&reg; for simulating <I>in vitro</I> mitochondrial function, SimPops&trade; for evaluating the impact of patient
variability, and a new product in development called NAFLDsym&trade; for the study of nonalcoholic fatty liver disease &ndash;
a worldwide disease with few available treatment options. For calendar year 2016, its most recent fiscal year, DILIsym Services,
Inc. revenues were just over $3 million with net earnings of approximately $720,000. More information is available on the company&rsquo;s
Web site at https://www.dilisym.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Safe Harbor Statement Under the Private
Securities Litigation Reform Act of 1995</B> &ndash; With the exception of historical information, the matters discussed in this
press release are forward-looking statements that involve a number of risks and uncertainties. Words like &ldquo;believe,&rdquo;
&ldquo;expect&rdquo; and &ldquo;anticipate&rdquo; mean that these are our best estimates as of this writing, but that there can
be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ
significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to:
our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by
our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to
attract and retain highly qualified technical staff, our ability to properly manage the new combined company, and a sustainable
market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and
Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>simulations_8k-ex9902.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.2</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"><IMG SRC="logo.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">For Further Information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Simulations Plus, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">42505 10<SUP>th</SUP> Street West</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Lancaster, CA 93534-7059</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt"><B>CONTACT</B>:</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: underline"><U>Simulations Plus Investor Relations</U></TD>
    <TD STYLE="text-decoration: underline"><U>Hayden IR</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Ms. Ren&eacute;e Bouch&eacute;</TD>
    <TD>Mr. Cameron Donahue</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>661-723-7723</TD>
    <TD>651-653-1854</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>renee@simulations-plus.com</TD>
    <TD>cameron@haydenir.com</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">For Immediate Release:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">May 1, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Dr. Daniel Weiner joins Simulations Plus
Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>World-renowned scientist, FDA consultant,
and experienced manager to reinforce SLP board</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>LANCASTER, CA, May 1, 2017 &ndash; </B>Simulations
Plus, Inc. (Nasdaq: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development,
today announced that Dr. Daniel Weiner, an expert on pharmacokinetic modeling and pharmacodynamics, has become a member of its
Board of Directors effective today, filling the vacancy created when Dr. David D&rsquo;Argenio retired from the board last year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Walt Woltosz, chairman and chief executive
officer of Simulations Plus, said: &ldquo;We&rsquo;re excited to announce that Dr. Daniel Weiner has become a member of the Simulations
Plus Board of Directors effective today. Dr. Weiner brings decades of directly relevant experience in pharmaceutical software development
and is world renown for his work in pharmacokinetics and pharmacodynamics.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Weiner has extensive drug development experience
and has served as an expert consultant to the U.S. Food and Drug Administration (FDA) on pharmacokinetic modeling and bioequivalence
assessment. Prior to his previous tenure with Certara/Pharsight as a Senior Vice President and Chief Science Officer, Dr. Weiner
held several management positions with Merrell Dow Pharmaceuticals; Statistical Consultants, Inc.; Syntex Development Research;
Quintiles; and IVAX Research. Dr. Weiner graduated from the University of Kentucky with a doctoral degree in Mathematical Statistics,
with emphasis on compartmental modeling. He is the original designer/author of the WinNonlin family of PK/PD Modeling Software
now used by over 1,000 institutions. He is the co-author of <I>Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and
Applications</I>, now in its fifth edition. Dr. Weiner is an Adjunct Associate Professor with the Division of Pharmacotherapy and
Experimental Therapeutics in the School of Pharmacy, University of North Carolina, and an Affiliate Professor of Pharmacometrics,
Center for Translational Medicine in the School of Pharmacy at the University of Maryland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Regarding his new appointment, Dr. Weiner stated,
&ldquo;Simulations Plus is a leader in the development of software products and providing consulting services that utilize quantitative
systems pharmacology (QSP) to support model-based drug development (MBDD), concepts for which I am a passionate advocate. I have
been very impressed with the quality of the science and scientists at Simulations Plus, and the solid corporation that Walt and
his team have built. I am both honored and pleased to accept a position on the Board of Directors, and look forward to assisting
the company in its endeavors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Simulations Plus, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Simulations Plus, Inc. is a premier developer
of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting
services for regulatory submissions. The company is a global leader focused on improving the ways scientists use knowledge and
data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our software is licensed to and used in
the conduct of drug research by major pharmaceutical and biotechnology companies and regulatory agencies worldwide. Our innovations
in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology
into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation.
For more information, visit our website at www.simulations-plus.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Follow us on Twitter <FONT STYLE="color: blue">| </FONT>LinkedIn</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">###</P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  P 0H# 2(  A$! Q$!_\0
M'    @(# 0$             !@< !0,$" $"_\0 .1   0,$ 0($ P4&!@,
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M&F@%EB_:$NIE[>ML1<<GNE"CR3_W1Q%ZQA029%I/$C84AWT_#5*SJ-=L%O\
MA<&=CS$:!D7)!<B,)UQ3OYDJUVK2:Y!B-IMQ22$))2@D:)&^];FXL,C;+*6"
M?(EB(IUI\0^K=D<($EB6R3Z\.0%'ELGQKG!:F074NQW1M*DUSWU*L$''9MJ1
M;&W4MRH_BN!1*OF_M3+Z'J4<.7LD@25ZWZ>58,G&B$0EC6G'R)3*8I*3!<<0
MT@K=6E"!YJ4= 56*R*S!? W2%R\M>,G_ +I-?:)O#KF16#'W);D2V/D.25I.
MNQ5K9]P!6^>GO3"7:ULP)L,RU(TV\9O?GKL2-^_I53<9H8U[R=_8+29G%Q:T
M#;RG,F0PI@OI>;4P!OQ H%.OQKYB2X\QKQ8C[;[>]<FU!0_44H[#:$]-^F=X
M3ELP7&W/*'%N,H_</;23]:O(F18Y@73JWW"% ?C6M\@M,;VOYCYDFJW0?9OO
M0\KH2_=MLF/4I7W#K/98H9?1;[F] <T/BPR4M@GTV?/\JR7?K%9(3:7XD.X3
MX6@5RF6M-()]"H^M1Z67[5/UH_=,RI0E-SVSQL(3E*%./6Y204A(THDG6M>]
M6<+(HTG%$7\H<:B*C_$\5_>XZW59C>!9'=?*[#VGM7*UI;0I:U!*4C9).@!6
M&)+CS6O%AOMOM[*>3:@H;]MBEGD^=1+[T?O%Y@-/,,NMJCH\7L25=MC]:UNG
M]YM?3WI!:)=W66_BOWJ6T#:UK5Z ?E5WIG:+[NJ5?UAJKJK3<J4K%]9(,4-O
M72P7J!!<(XRGF=(/U%:W6?J/)L%JB,8^'D3)8;>;EEKDUX9/<=_-7TJ&XLI<
M&URAG8 3?";E:S4Z(])7':DLKD-_?;2L%2?Q% F$=0579<*WS+5=6I/@<GI3
M['!O83LG\ZU, NF(/2LDR2UPW8:FEE,R6\HD*UW.N_:H,#FWJ'"GZH-4F?4I
M5JZT6Q:%OP++>)D)!.Y+;/R:'K178<YL]\Q:5?H+BS$BH4IY*AI2"D;(J'8\
MC!;@I;*QVP**:E*]KK-9I5K$NWVZYS%@GFTRSLMI]U'R%$>,9_9,AQZ7>([R
MF8T/?Q*71HM'6]&CL>1HLM02L<:!1;4\N]*T]8HCS*I5NQV]S;<G9,MIG]WH
M>M$MHS*VY'ADR]6Q2_ ;0XA25IXE*@/*CL>1N[@@E8>"B W:WI409L8$'1'B
M"LC$Z))5QCR67%>R%@FD[TRPJVY'9Y%PO#3BW%O$(*5E(UZ_SK!E%@B8YF]E
MB8ZMYI]U:2I/,DCO_P#:T>EC+S&'&QXV67U4@8)"T4?.Z=BI4=$A,=3S8?5Y
M-E0Y'\JS4JHCJ)W5ZZW!SNS;(Q)^G$:-'6*9'&R6WN3(;;K;*'"W^\&MZ]15
M$L!8 1["_E7Q3AY(/N:^%=U*&[/E]ON<BZ(;#C;=O)\5U?W?RJH/4>,ZE;MO
ML]SFQ$[W(::^3MZU @D)JE)GC NT=U*H\5R>!DT5QZW*7MH\7$+3HI-7E5N:
M6'2X;JQK@\:FG9)O[2[:GL?LC;:_#<7/0E#G_!1/8_K0=EV?Y;A]S1:<JLUI
MO+S;*5)F&.2'$GZZ/?WII=<<4F97AI9M@YS8SH?0WO17KS /O231GO4+'HB(
M5W@)EQV1I/Q\0D@?^6N]>KB 21 4#5['8K',=#R38OM$F<6^S91T61E[=D8L
M]T1IP>&GB3\VB/(;!K4Q3.9^/6*+!BP8;[6TKYO#:OF(W07F/4G(,RMK5HEM
MQ8\+FD^!%01S(\@?I5M&M\QQEI+41]PI2!\C9/>MD<-,TR\7=7PL.3-_(.BY
M3CZD9I-L$FT(C08<A,J/XJB\G?$^P^E6O1V0J9CDR6M"4+?FN.*0@:2DG78?
M2E&C&\HN[C?BPYSZ@.*%2-CB/8;\A3QZ=X^]C>-MPY2PM]2RZOCY))]*\_)9
M'%#H!&I:,9\DLVL@Z4"7_*<7R//I&+Y39XWA100B9(<UW\] >GZT-]3L9Z<V
M;%9DFUN,MW+CJ,F.]LE?X>U-S).G^-9',,JZVUMR2H *<22A2OQ(\ZHHG3OI
M];;FAH18?Q@(XLO2.1)]/E)KB/(C9I(+A777^5J=$]U@@'RE/D1E1^BV*6>8
MXXJ1<I@6$N$E7A$]AW_$44=:F Z[@F*H_C<0E:!ZC03_ %%,R_6?%;O>+<+H
MJ&N=!4/AFB\$E!V"!QW]!7U>[3C$C((5ZNSD47&*.+#CCX3QT=^6]>=!EML.
MKBS\GA0<=U$?C](&^T.\U P2W6>.EMOXF2VT$I &DCL=?J*W.I@8Q?HFJ&RT
MTV? :8">(&U'6S^/G1G?;!C^528*[DAF8[$/C,!+OELCYM ]QV%>Y?:\?OUK
M2SD*V%PFW-[6]P2%CTWO^55,G: QIZ-E=NB<2XCL4$D.H#?[$Z(XC9CM!ENH
M6X??1WW_ "-&G57)+58NE*K9#GL.2GHR&&$-+"B0-;/;R&A1O?;=C%[QYF+=
M507K6G26E%T #0U\JMU3V_II@[]I4Q"M\=^*XOD7$.E9)'IRWY?2K!D1NTE]
M[$E<F%XO3V*2NSEDVGHEB5B;&G9[J5%/OWY?W%$N87Z3"OV/819F;>W($="E
M2YK84EH$?P[]>QID7S%+#<!;W[I&046L L%2RE+8 [;]/UJOR/',/S%DR[F(
M<I,8<52&GPDH'L5)/]:#)8:U#W/R4,+MZ\?I*#JZJ_,P+=8+GD$"\-SY"0 T
M@)=;.^WE_#5OU?#3N1X%C2W$,L(4A3G,Z2.P )/_ *T=VS!\$XQI$!B&Y^SU
MAQ+R9'(I.]@J.^_YUN95:\,RQ+0O3T"0ILZ0L20E0^FP:D93 6^+Z'?A08'$
M'S2K+WU"M;\?*;=;^2E6R$HN20!X7(CB$@^^S2B=2Y:?LZ,J')*[M-"UJ]T[
MT=_CJGA;<1Q!=@E6.VLQ5P9&O';9>Y*7H]N1!WVJT.-V&1CXL2HL=VVQP$^
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C<-#@3/B-J:9?5KR"%'L1[BF7H:UH:KT#7D-"B*5*E2B+_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
